Proangiogenic factors, including VEGF and angiopoietin-2, are known to promote recruitment of tumor promoting macrophages, and preclinical models illustrate modulation of the tumor vasculature by anti-angiogenic agents may reduce these macrophages and induce immune response by increasing immune effector cell infiltration when combined with immunotherapy [38, 39]. Here, ANGPT2 is linked to neoplasm.